2017 American Transplant Congress
CD19+CD38hiCD24hi Immature Transitional B Cells in PBMCs of Tolerant Kidney Recipients of Facilitating Cell-Enriched Hematopoietic Stem Cells and Renal Allografts.
CD19+CD38hiCD24hi immature transitional B cells may represent a biomarker for transplantation tolerance in kidney transplant (KTx) recipients (Cherukuri A, et al. J Am Soc Nephrol.…2016 American Transplant Congress
Alloantibody Suppression by Bruton Tyrosine Kinase Antagonist Ibrutinib Is Associated with a Moderate Splenic B-Cell Reduction.
Comprehensive Transplantation Center/Surgery, Cedars-Sinai Medical Center, Los Angeles, CA.
Background Bruton tyrosine kinase (Btk) is specifically required for activation of the B-cell antigen receptor signaling pathway that contributes to the initiation and maintenance of…2016 American Transplant Congress
Acquired Down-Regulation of B Cell Function Induced by Donor Blood Group Antigens After ABO-Incompatible Kidney Transplantation.
Background: The long-term of B cell immunobiology against donor blood group antigen has not been elucidated in ABO incompatible kidney transplantation (ABOi KTx).Methods: The antibody…2016 American Transplant Congress
B Cell Signature Profiling in Kidney Transplant Patients on Thymoglobulin.
Purpose: B cell subsets could be used as biomarkers to modulate therapy regimens in kidney transplant patients. B cell subsets occur with varying proportions within…2016 American Transplant Congress
HLA Antibody Clonality and Epitopes Dictate Complement Activation.
Background: Alloimmunization results in production of polyclonal donor specific antibodies (DSA) against human leukocyte antigens (HLA), which mediate endothelial cell activation, leukocyte recruitment, and complement…2016 American Transplant Congress
First Experience with Obinutuzumab (Type II Anti-CD20) in Patients with Treatment-Resistant Glomerular Diseases and Antibody-Mediated Rejection.
Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA.
Introduction: There is extensive experience with rituximab (RTX,Type I anti-CD20) for desensitization (DES) and treatment of ABMR. There is also a comparable experience in treatment…2016 American Transplant Congress
Everolimus Decline Anti-ABO Blood Type Antibody Titer in Desensitization for ABO Incompatible Kidney Transplantation.
Kidney Transplantation Surgery, Sapporo City General Hospital, Sapporo, Hokkaido, Japan.
INTRODUCTION: The immoderate donor shortage and sophisticated desensitization protocols resulted in the explosive increase and great success of the ABO blood type incompatible kidney transplantation…2016 American Transplant Congress
Initial Experience with the Bacterial Enzyme IdeS® (IgG Endopeptidase) for Desensitization of Highly-HLA Sensitized (HS) Patients.
Introduction: The IgG degrading enzyme derived from Streptococcus pyogenes (IdeS®) is a 35k-Da cysteine protease that cleaves human IgG molecules at the lower hinge region…2016 American Transplant Congress
The Effect of Rituximab on Hepatitis B Reactivation in Kidney Transplant Recipients with Resolved Hepatitis B.
Background: Hepatitis B virus (HBV) reactivation is a well-known complication of immunosuppressive therapy in resolved HBV (hepatitis B surface antigen [HBsAg] negative and hepatitis B…2016 American Transplant Congress
A Prospective Carfilzomib-Based Desensitization Trial: Phase 1 Results.
1U Of Cincinnati, Cincinnati; 2Mayo Clinic, Phoenix.
Carfilzomib (CFZ) is mechanistically distinct from bortezomib as it is an irreversible PI. Results from phase 1 of a CFZ desensitization (DS) trial are presentedMethods:…
- « Previous Page
- 1
- …
- 25
- 26
- 27
- 28
- 29
- …
- 35
- Next Page »